737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

• Brendan Curti,
• Igor Puzanov,
• Mateusz Opyrchal,
• Christopher J Nirschl,
• Mehmet A Bilen,
• Kristin Morris,
• Justin C Moser,
• Ildefonso Rodriguez Rivera,
• Saero Park,
• Marissa Bruno,
• Paul Windt,
• Kulandayan K Subramanian,
• Sameer S Chopra,
• Randi Isaacs

Affiliations

Brendan Curti

3Providence Cancer Institute, Franz Clinic, Portland, OR, USA

Igor Puzanov

9Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Mateusz Opyrchal

Aff62 grid.240614.50000000121818635Roswell Park Cancer Institute Buffalo NY USA

Christopher J Nirschl

Aff1 grid.21107.350000000121719311OncologyJohns Hopkins School of Medicine Baltimore MD USA

Mehmet A Bilen

Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

Kristin Morris

1Werewolf Therapeutics, Cambridge, MA, United States

Justin C Moser

1HonorHealth Research Instittue, Scottsdale, AZ, USA

Ildefonso Rodriguez Rivera

3NEXT Oncology/Texas Oncology, San Antonio, TX, USA

Saero Park

7Werewolf Therapeutics, Watertown, MA, USA

Marissa Bruno

7Werewolf Therapeutics, Watertown, MA, USA

Paul Windt

7Werewolf Therapeutics, Watertown, MA, USA

Kulandayan K Subramanian

7Werewolf Therapeutics, Watertown, MA, USA

Sameer S Chopra

7Werewolf Therapeutics, Watertown, MA, USA

Randi Isaacs

7Werewolf Therapeutics, Watertown, MA, USA